Apr 29th, 2009 - Wall Street Journal
NEW YORK (Dow Jones)--Dendreon Corp. (DNDN) has cleared a significant hurdle in bringing its controversial prostate cancer treatment Provenge to market, but obstacles remain before the drug gets launched.
Provenge could be a blockbuster drug, with the potential to revolutionize cancer treatment by harnessing the immune system to fight the disease, but the Seattle drug developer still must pass a cautious Food and Drug Administration, including the resolution of manufacturing questions.
Related stories:
New Jersey reports 5 confirmed cases of H1N1 flu
Apr 30th, 2009 - Reuters
PHILADELPHIA, April 30 (Reuters) - New Jersey Governor JonCorzine said on Thursday that five cases of H1N1 influenza havebeen confirmed in New Jersey residents after the state receivedtest results from the Centers for Disease Control andPrevention.
Chrysler: Obama's Automotive Guinea Pig
Apr 29th, 2009 - Forbes
Chrysler will survive and avoid liquidation through an alliance with Italy's Fiat, but whether that happens in or out of bankruptcy remains uncertain, sources familiar with the matter said. On Thursday...
BIOTECH STOCKS Dendreon shines as drug stocks climb
Apr 29th, 2009 - MarketWatch
BOSTON (MarketWatch) -- Dendreon Corp. led drug stocks higher in afternoon trading Wednesday as shares of the biotech group rocketed on results from a positive study for its prostate cancer therapy Provenge.
Q+AU.S. Treasury's 'second-lien' mortgage relief plan
Apr 28th, 2009 - Reuters
April 28_(Reuters) - The Obama administration on Tuesdayunveiled new incentives to modify and extinguish second-lienmortgages to reduce monthly payments for struggling homeowners.
Seaspan, Dendreon: Biggest Price Decliners (SSW, DNDN)
Apr 28th, 2009 - Wall Street Journal
Seaspan Corp. topped the list of Biggest Percentage Price Decliners among common stocks on the New York Stock Exchange at the close on Tuesday. See the full list . Dendreon Corp...
